Regulators have given their blessing to Brovana, a drug from
that treats airways that have been constricted because of chronic obstructive pulmonary disease.
The drug is a long-acting solution meant to be used with a nebulizer, a device that converts liquid into a fine mist. The Food and Drug Administration approval was announced late Friday.
Following the regulatory clearance, shares of Sepracor were up 97 cents, or 2%, to $51.17 Monday.
"The approval of Brovana adds another important treatment option to Sepracor's respiratory franchise," said Sepracor President and Chief Operating Officer W. James O'Shea in a company press release.
O'Shea expects the drug to go on sale in the second quarter of 2007.
Chronic obstructive pulmonary disease, or COPD, is a lung disease that includes two main illnesses, chronic bronchitis and emphysema. Smoking is the primary cause.